AMRS - Amyris Inc Stock Price, Fair Value and News

0.01USD0.00 (0.00%)Delayed

Market Summary

USD0.010.00

Delayed

0.00%

AMRS Stock Price

View Fullscreen

AMRS RSI Chart

AMRS Valuation

Market Cap

3.7M

Price/Earnings (Trailing)

-0.01

Price/Sales (Trailing)

0.01

EV/EBITDA

-1.14

Price/Free Cashflow

-0.01

AMRS Price/Sales (Trailing)

AMRS Profitability

Free Cashflow Yield

-12.5K%

AMRS Fundamentals

AMRS Revenue

AMRS Earnings

Breaking Down AMRS Revenue

Last 7 days

-75%

Last 30 days

-80%

Last 90 days

-98.9%

Trailing 12 Months

-99.6%

How does AMRS drawdown profile look like?

AMRS Financial Health

AMRS Investor Care

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	268.2M	0	0	0
2022	222.7M	235.6M	258.8M	269.8M
2021	320.9M	343.2M	356.8M	341.8M
2020	167.3M	134.6M	133.9M	173.1M
2019	60.1M	107.8M	128.4M	152.6M
2018	148.3M	137.7M	127.8M	63.6M
2017	71.4M	87.4M	85.1M	143.4M
2016	35.1M	36.8M	54.8M	67.2M
2015	45.1M	43.6M	35.9M	34.2M
2014	39.3M	37.7M	47.1M	43.3M
2013	52.1M	43.7M	31.6M	41.1M
2012	139.3M	126.5M	109.4M	73.7M
2011	103.8M	123.1M	135.2M	147.0M
2010	0	69.8M	75.1M	80.3M
2009	0	0	0	64.6M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Amyris Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Jun 02, 2023	kieftenbeld hermanus	sold	-19,949	0.95	-20,999	chief financial officer
Apr 19, 2023	qi lisa	acquired	-	-	10,537	-
Apr 19, 2023	panchadsaram ryan	acquired	-	-	9,667	-
Apr 19, 2023	doerr l john	acquired	-	-	11,600	-
Apr 19, 2023	mccann james f	acquired	-	-	13,437	-
Apr 05, 2023	alvarez eduardo	sold	-284,305	1.2288	-231,368	chief operating officer
Apr 04, 2023	alvarez eduardo	acquired	-	-	492,000	chief operating officer
Jan 20, 2023	qi lisa	acquired	-	-	7,532	-
Jan 20, 2023	panchadsaram ryan	acquired	-	-	7,947	-
Jan 20, 2023	doerr l john	acquired	-	-	8,292	-

Which funds bought or sold AMRS recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Feb 15, 2024	BARCLAYS PLC	sold off	-100	-2,000	-	-%
Feb 14, 2024	Badgley Phelps Wealth Managers, LLC	sold off	-100	-600	-	-%
Feb 14, 2024	Williams Jones Wealth Management, LLC.	sold off	-100	-930	-	-%
Feb 14, 2024	Bill & Melinda Gates Foundation	sold off	-100	-17,544	-	-%
Feb 13, 2024	XTX Topco Ltd	sold off	-100	-4,817	-	-%
Feb 13, 2024	StepStone Group LP	unchanged	-	-1,683	7.00	-%
Feb 13, 2024	AlphaCore Capital LLC	sold off	-100	-642	-	-%
Feb 12, 2024	Steward Partners Investment Advisory, LLC	sold off	-100	-16.00	-	-%
Feb 12, 2024	Glassman Wealth Services	sold off	-100	-295	-	-%
Feb 08, 2024	Baader Bank Aktiengesellschaft	sold off	-100	-1,164	-	-%

Are Funds Buying or Selling AMRS?

Are funds buying AMRS calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own AMRS

No. of Funds

Unveiling Amyris Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Jan 05, 2024	foris ventures, llc	30.3%	122,898,614	SC 13D/A
Dec 14, 2023	foris ventures, llc	30.3%	122,726,324	SC 13D/A
Oct 16, 2023	foris ventures, llc	30.2%	122,255,166	SC 13D/A
Oct 05, 2023	foris ventures, llc	30.2%	122,178,837	SC 13D/A
Oct 02, 2023	foris ventures, llc	30.2%	122,140,768	SC 13D/A
Sep 20, 2023	foris ventures, llc	30.2%	122,034,555	SC 13D/A
Aug 10, 2023	foris ventures, llc	29.9%	120,499,897	SC 13D/A
Aug 03, 2023	foris ventures, llc	29.9%	120,480,436	SC 13D/A
Jun 30, 2023	foris ventures, llc	29.9%	120,385,914	SC 13D/A
Jun 09, 2023	foris ventures, llc	29.9%	120,319,193	SC 13D/A

Recent SEC filings of Amyris Inc

View All Filings

Date Filed	Form Type	Document
Apr 23, 2024	8-K	Current Report
Apr 08, 2024	8-K	Current Report
Apr 02, 2024	NT 10-K	NT 10-K
Feb 28, 2024	8-K	Current Report
Feb 21, 2024	EFFECT	EFFECT
Feb 21, 2024	EFFECT	EFFECT
Feb 21, 2024	EFFECT	EFFECT
Feb 21, 2024	EFFECT	EFFECT
Feb 21, 2024	EFFECT	EFFECT
Feb 21, 2024	EFFECT	EFFECT

Peers (Alternatives to Amyris Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
APD	52.0B	12.4B	-1.27%	-20.32%	22.25	4.19	-3.54%	3.06%
DOW	40.0B	44.6B	-1.61%	2.46%	60.68	0.9	-21.58%	-85.78%
AVTR	17.4B	7.0B	-1.61%	27.30%	54.18	2.5	-7.26%	-53.23%
CE	17.0B	10.9B	-5.63%	47.70%	8.67	1.55	13.10%	3.48%
ALB	13.4B	9.6B	-5.52%	-37.93%	8.52	1.39	31.38%	-41.50%
EMN	11.4B	9.2B	1.63%	17.76%	12.71	1.23	-12.95%	12.74%
MID-CAP
CBT	5.2B	3.9B	3.43%	24.94%	11.64	1.32	-9.12%	26.64%
BCPC	4.7B	922.4M	-6.77%	12.46%	43.13	5.07	-2.11%	3.01%
AVNT	3.9B	3.1B	4.71%	9.92%	51.93	1.26	-7.48%	-89.19%
ARCH	2.9B	3.1B	-3.66%	24.21%	6.23	0.91	-15.54%	-65.21%
SMALL-CAP
CCF	1.2B	404.0M	0.11%	32.60%	36.59	3	24.06%	-25.72%
ASIX	725.4M	1.5B	1.53%	-30.74%	13.28	0.47	-21.18%	-60.55%
CMT	176.9M	357.7M	5.18%	0.56%	8.71	0.49	-5.20%	66.55%
AREC	105.7M	16.7M	-6.76%	14.05%	9.54	6.31	-57.58%	866.09%
AMRS	3.7M	-	-80.00%	-99.58%	-0.01	0.01	-	-

Amyris Inc News

Latest updates

Amyris Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4	2018Q3	2018Q2	2018Q1
Revenue	-26.0%	56,083,000	75,802,000	71,129,000	65,207,000	57,709,000	64,776,000	47,866,000	52,316,000	176,859,000	79,744,000	34,258,000	30,005,000	29,130,000	40,536,000	34,953,000	62,694,000	14,374,000	16,371,000	14,315,000	15,059,000	17,859,000
Costs and Expenses	5.7%	241,612,000	228,626,000	219,307,000	208,628,000	182,269,000	193,634,000	134,711,000	107,185,000	83,913,000	82,723,000	82,340,000	70,566,000	60,930,000	72,416,000	73,027,000	65,205,000	63,799,000	65,032,000	52,258,000	41,657,000	41,240,000
S&GA Expenses	-29.2%	95,870,000	135,417,000	124,709,000	126,587,000	106,916,000	94,914,000	70,635,000	54,340,000	37,922,000	36,233,000	38,321,000	30,503,000	32,014,000	34,130,000	33,341,000	30,862,000	28,253,000	26,109,000	27,239,000	19,454,000	18,100,000
R&D Expenses	-7.6%	26,765,000	28,966,000	28,780,000	26,111,000	26,358,000	24,709,000	23,824,000	22,424,000	23,332,000	19,388,000	18,197,000	16,965,000	17,126,000	15,367,000	19,032,000	19,222,000	17,839,000	18,783,000	16,445,000	15,669,000	17,825,000
EBITDA Margin	-17.2%	-2.18	-1.86	-1.21	-0.78	-0.26	-0.70	-1.08	-1.08	-1.49	-1.54	-1.51	-1.96	-	-	-	-	-	-	-	-	-
Interest Expenses	64.8%	12,983,000	7,877,000	6,289,000	5,304,000	5,263,000	10,748,000	4,321,000	4,723,000	5,813,000	6,204,000	6,627,000	20,118,000	15,002,000	42,948,000	16,857,000	15,217,000	12,534,000	13,965,000	9,180,000	9,580,000	9,978,000
Income Taxes	36.0%	-860,000	-1,344,000	152,000	-685,000	-820,000	-8,284,000	58,000	57,000	55,000	20,000	83,000	99,000	91,000	96,000	533,000	-	-	-	-	-	-
Earnings Before Taxes	-33.3%	-202,636,000	-152,006,000	-167,122,000	-109,233,000	-110,264,000	35,517,000	-34,084,000	16,644,000	-290,388,000	-107,568,000	-21,005,000	-107,939,000	-87,338,000	-78,778,000	-59,029,000	-38,088,000	-66,243,000	-48,598,000	-74,453,000	-14,382,000	-92,802,000
EBT Margin	-17.9%	-2.35	-2.00	-1.36	-0.93	-0.41	-0.80	-1.16	-1.17	-1.64	-1.87	-2.20	-2.47	-	-	-	-	-	-	-	-	-
Net Income	-36.0%	-201,776,000	-148,333,000	-161,395,000	-110,013,000	-110,233,000	37,845,000	-32,944,000	15,381,000	-291,251,000	-110,670,500	-23,156,000	-108,315,000	-87,844,000	-78,874,000	-59,562,000	-38,088,000	-66,243,000	-48,598,000	-74,453,000	-14,382,000	-92,802,000
Net Income Margin	-18.0%	-2.32	-1.96	-1.33	-0.91	-0.40	-0.79	-1.18	-1.19	-1.66	-1.91	-2.23	-2.49	-	-	-	-	-	-	-	-	-
Free Cashflow	3.1%	-90,001,000	-92,877,000	-133,534,000	-147,041,000	-152,442,000	-142,170,000	-69,368,000	-78,446,000	108,651,000	-9,940,000	-55,481,000	-63,957,000	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4	2018Q3	2018Q2	2018Q1
Assets	-17.6%	680	825	754	789	898	954	542	446	327	266	206	268	167	161	128	123	105	128	123	119	118
Current Assets	-20.5%	244	306	272	310	471	639	278	349	252	147	131	191	85.00	74.00	55.00	46.00	36.00	92.00	68.00	67.00	74.00
Cash Equivalents	-82.5%	11.00	64.00	18.00	100	288	488	115	214	144	30.00	38.00	100	3.00	2.00	2.00	1.00	5.00	47.00	19.00	14.00	24.00
Inventory	-2.6%	109	112	129	99.00	82.00	75.00	72.00	54.00	48.00	43.00	37.00	33.00	31.00	28.00	16.00	14.00	8.00	10.00	6.00	7.00	5.00
Net PPE	4.1%	190	182	170	151	125	73.00	53.00	42.00	32.00	33.00	30.00	27.00	27.00	29.00	24.00	24.00	22.00	20.00	17.00	15.00	13.00
Goodwill	-64.6%	50.00	143	127	134	1.00	131	129	4.00	-	-	-	-	-	-	-	-	-	-	-	-	-
Liabilities	2.7%	1,328	1,293	1,159	1,033	1,024	675	596	528	637	461	285	327	343	411	336	298	337	340	323	368	404
Current Liabilities	21.6%	471	387	309	187	266	270	460	95.00	147	163	104	129	192	161	159	190	236	212	154	159	111
Long Term Debt	0.1%	676	675	674	673	672	309	12.00	14.00	14.00	-	25.00	37.00	46.00	26.00	63.00	0.00	60.00	-	44.00	44.00	62.00
LT Debt, Current	2.7%	2.00	2.00	2.00	1.00	1.00	1.00	25.00	1.00	56.00	55.00	31.00	43.00	77.00	45.00	65.00	79.00	129	124	62.00	60.00	34.00
LT Debt, Non Current	0.1%	676	675	674	673	672	309	12.00	14.00	14.00	26.00	26.00	24.00	12.00	48.00	20.00	10.00	43.00	43.00	44.00	44.00	62.00
Shareholder's Equity	-	-	-	-	-	-	246	-	-	-	-	-	-	0.00	-	-	5.00	1.00	1,347	-	-	-
Retained Earnings	-6.7%	-3,073	-2,880	-2,730	-2,568	-2,458	-2,357	-2,395	-2,362	-2,377	-2,086	-1,977	-1,953	-1,843	-1,755	-1,676	-1,617	-1,579	-1,521	-1,367	-1,298	-1,300
Additional Paid-In Capital	0.4%	2,466	2,456	2,384	2,357	-	2,657	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Shares Outstanding	1.0%	369	365	325	321	313	309	287	320	268	204	189	170	-	-	-	-	-	-	-	-	-
Minority Interest	24.4%	-9.76	-12.91	-13.10	-6.60	-3.52	-0.75	2.00	6.00	6.00	5.00	4.00	3.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00
Float	-	-	-	-	340	-	-	-	2,673	-	-	-	517	-	-	-	227	-	-	-	-	-

Cashflow (Last 12 Months)

(In Thousands)

Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4	2018Q3	2018Q2	2018Q1
Cashflow From Operations	3.1%	-90,001	-92,877	-133,534	-147,041	-152,442	-142,170	-69,368	-78,446	108,651	-9,940	-55,481	-63,957	-46,375	-43,466	-55,210	-21,277	-36,980	-19,919	-34,959	-29,319	-25,169
Share Based Compensation	-52.7%	5,785	12,220	12,256	12,647	11,588	11,461	8,905	8,747	4,281	3,870	3,438	2,931	3,504	2,493	3,234	3,375	3,452	3,075	2,937	1,900	1,278
Cashflow From Investing	-9.5%	-4,815	-4,399	-30,086	-41,936	-47,286	-23,517	-34,911	-3,177	-2,493	-3,162	-4,125	-4,454	-1,040	-4,067	-3,062	-2,905	-3,046	-6,110	-1,998	-2,780	-1,584
Cashflow From Financing	-70.9%	41,614	142,906	81,287	3,262	3,958	537,908	4,816	151,709	7,529	9,187	-1,949	165,624	49,663	46,168	58,688	20,276	-222	51,797	41,387	21,467	-6,694

AMRS Income Statement

2023-03-31

Condensed Consolidated Statements of Operations - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Revenue:
Revenue	$ 56,083	$ 57,709
Cost and operating expenses:
Cost of products sold	51,081	48,995
Research and development	26,765	26,358
Sales, general and administrative	95,870	106,916
Change in fair value of acquisition-related contingent consideration	(28,503)	0
Restructuring	1,013	0
Impairment	95,386	0
Total cost and operating expenses	241,612	182,269
Loss from operations	(185,529)	(124,560)
Other income (expense):
Interest expense	(12,983)	(5,263)
Gain from change in fair value of derivative instruments	1,263	1,815
(Loss) gain from change in fair value of debt	(4,854)	20,796
Other expense, net	(533)	(3,052)
Total other (expense) income, net	(17,107)	14,296
Loss before income taxes and loss from investment in affiliate	(202,636)	(110,264)
Benefit from income taxes	860	820
Loss from investment in affiliate	0	(789)
Net loss	(201,776)	(110,233)
Loss attributable to noncontrolling interest	8,434	2,928
Net loss attributable to Amyris, Inc. common stockholders	$ (193,342)	$ (107,305)
Earnings Per Share [Abstract]
Net loss per share attributable to common stockholders, basic (in dollars per share)	$ (0.53)	$ (0.34)
Weighted-average shares of common stock outstanding used in computing net loss per share of common stock, basic (in shares)	365,603,738	312,896,452
Net loss per share attributable to common stockholders, diluted (in dollars per share)	$ (0.53)	$ (0.37)
Weighted-average shares of common stock outstanding used in computing net loss per share of common stock, diluted (in shares)	365,603,738	323,711,682
Renewable Products
Revenue:
Revenue	$ 40,224	$ 43,465
Licenses and Royalties
Revenue:
Revenue	9,482	9,313
Collaborations, Grants and Other
Revenue:
Revenue	$ 6,377	$ 4,931

AMRS Balance Sheet

2023-03-31

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 11,245	$ 64,437
Restricted cash	71	71
Accounts receivable, net of allowance of $997 and $995	36,842	45,775
Accounts receivable - related party, net of allowance of $0 and $0	10,836	6,608
Contract assets	3,872	806
Contract assets - related party	33,679	36,638
Inventories	109,021	111,880
Prepaid expenses and other current assets	38,095	40,146
Total current assets	243,661	306,361
Property, plant and equipment, net	189,645	182,224
Restricted cash, noncurrent	6,135	6,090
Recoverable taxes from Brazilian government entities	30,189	29,472
Right-of-use assets under financing leases, net	147	152
Right-of-use assets under operating leases, net	100,721	97,216
Goodwill	50,456	142,575
Intangible assets, net	45,063	46,938
Other assets	13,662	13,904
Total assets	679,679	824,932
Current liabilities:
Accounts payable	200,067	190,486
Accrued and other current liabilities	81,068	73,565
Financing lease liabilities	14	13
Operating lease liabilities	2,484	2,255
Contract liabilities	33	26
Debt, current portion	1,968	1,916
Related party debt, current portion	185,160	118,886
Total current liabilities	470,794	387,147
Long-term debt, net of current portion	675,855	674,891
Related party debt, net of current portion	77,962	97,350
Financing lease liabilities, net of current portion	44	48
Operating lease liabilities, net of current portion	90,986	86,195
Derivative liabilities	4,140	5,403
Acquisition-related contingent consideration	2,241	34,555
Other noncurrent liabilities	5,725	7,053
Total liabilities	1,327,747	1,292,642
Commitments and contingencies
Mezzanine equity:
Contingently redeemable common stock	0	5,000
Contingently redeemable noncontrolling interest	26,058	28,892
Stockholders’ (deficit) equity:
Common stock - $0.0001 par value, 550,000,000 shares authorized as of March 31, 2023 and December 31, 2022; 368,524,240 and 364,745,266 shares issued and outstanding as of March 31, 2023 and December 31, 2022	37	36
Additional paid-in capital	2,465,802	2,455,567
Accumulated other comprehensive loss	(56,682)	(64,114)
Accumulated deficit	(3,073,520)	(2,880,178)
Total Amyris, Inc. stockholders’ (deficit) equity	(664,363)	(488,689)
Noncontrolling interest	(9,763)	(12,913)
Total stockholders' (deficit) equity	(674,126)	(501,602)
Total liabilities, mezzanine equity and stockholders' (deficit) equity	$ 679,679	$ 824,932

About Amyris Inc

Amyris, Inc. operates as a biotechnology company in Europe, North America, Asia, South America, and internationally. It creates, manufactures, and commercializes consumer products and ingredient, including clean beauty, personal care, and health and wellness consumer products; and ingredients to the flavor and fragrance, nutrition, food and beverage, and clean beauty and personal care end markets. The company markets its products under the Biossance, JVN, Rose Inc., Pipette, Costa Brazil, OLIKA, Purecane, Terasana, MenoLabs, EcoFabulous, Stripes, and 4U by Tia brand names. It has a collaboration and license agreement with the Infectious Disease Research Institute for the development of a COVID-19 vaccine. The company was formerly known as Amyris Biotechnologies, Inc. and changed its name to Amyris, Inc. in June 2010. Amyris, Inc. was incorporated in 2003 and is headquartered in Emeryville, California. On August 9, 2023, Amyris, Inc., along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.

CEO	Mr. Hermanus Kieftenbeld
WEBSITE	https://amyris.com
INDUSTRY	Chemicals
EMPLOYEES	1598

Amyris Inc Frequently Asked Questions

What is the ticker symbol for Amyris Inc? What does AMRS stand for in stocks?

AMRS is the stock ticker symbol of Amyris Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Amyris Inc (AMRS)?

As of Fri Oct 20 2023, market cap of Amyris Inc is 3.69 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of AMRS stock?

You can check AMRS's fair value in chart for subscribers.

What is the fair value of AMRS stock?

You can check AMRS's fair value in chart for subscribers. The fair value of Amyris Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Amyris Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for AMRS so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Amyris Inc a good stock to buy?

The fair value guage provides a quick view whether AMRS is over valued or under valued. Whether Amyris Inc is cheap or expensive depends on the assumptions which impact Amyris Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for AMRS.

What is Amyris Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Oct 20 2023, AMRS's PE ratio (Price to Earnings) is -0.01 and Price to Sales (PS) ratio is 0.01. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. AMRS PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Amyris Inc's stock?

In the past 10 years, Amyris Inc has provided -0.561 (multiply by 100 for percentage) rate of return.